Clinical Trials for Liver Cancer

A Pilot Study of Liver Protection Using Prednisone for Patients Receiving Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

HealthScout AI summary: Adults with hepatocellular carcinoma receiving SBRT who are at higher risk for post-radiation hepatic decompensation (e.g., ALBI ≥ −1.81, cumulative target ≥4 cm, or Child-Pugh ≥7) receive short-course oral prednisone starting before and during SBRT to reduce hepatic inflammation and radiation-induced liver toxicity. Prednisone is a corticosteroid (glucocorticoid receptor agonist) with anti-inflammatory/immunosuppressive effects; prior liver-directed therapy allowed if recovered.

ClinicalTrials.gov ID: NCT05901519

An Open Label Phase II Study of Atezolizumab, Bevacizumab and Memantine in Patients With Hepatocellular Carcinoma

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

HealthScout AI summary: Adults with untreated, locally advanced/unresectable hepatocellular carcinoma (Child-Pugh A5–A6, ECOG 0–1) receive atezolizumab (PD-L1 inhibitor) plus bevacizumab (anti-VEGF) with the addition of memantine, an oral uncompetitive NMDA receptor antagonist being investigated to enhance antitumor activity. Key exclusions include Child-Pugh B/C, significant infections, recent major cardiovascular events, untreated/symptomatic CNS metastases or varices, prior memantine use, and mixed HCC histologies.

ClinicalTrials.gov ID: NCT06789757

A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Advanced Liver Cancers (Morpheus-Liver)

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

HealthScout AI summary: Adults with unresectable, locally advanced or metastatic HCC eligible for first-line therapy (ECOG 0–1, Child-Pugh A; exclusions include prior systemic therapy and high-risk portal hypertension) are randomized to atezolizumab/bevacizumab versus multiple immunotherapy-based combinations. Experimental arms include additions such as anti-TIGIT (tiragolumab), anti–IL-6R (tocilizumab), PPARα antagonist (TPST-1120/amezalpat), PD-1/LAG-3 bispecific (tobemstomig), masked anti–CTLA-4 (ADG126/muzastotug), anti-LILRB2 myeloid checkpoint (IO-108), or HIF-2α inhibitor (NKT2152/imdatifan), with adaptive crossover allowed after loss of benefit or toxicity.

ClinicalTrials.gov ID: NCT04524871

A Phase 1, Open-Label Study of ABSK-011 to Assess Safety, Tolerability, and Pharmacokinetics in Patients With Advanced Solid Tumors

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

HealthScout AI summary: Enrolling adults with advanced solid tumors for dose escalation and a biomarker-selected expansion in FGF19-overexpressing BCLC B/C hepatocellular carcinoma (Child-Pugh A–B7), after or unsuitable for first-line systemic therapy. Patients receive oral irpagratinib (ABSK-011), a selective covalent FGFR4 inhibitor targeting FGF19–FGFR4 signaling, given QD or BID in 28-day cycles.

ClinicalTrials.gov ID: NCT04906434

Phase II Single Arm Study of Tremelimumab and Durvalumab (MEDI4736) (T300+D) in Advanced Hepatocellular Carcinomas with Child-Pugh-B Cirrhosis (STRIDE in CP-B)

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

HealthScout AI summary: Adults with advanced HCC (BCLC B not eligible for locoregional therapy or BCLC C) and Child-Pugh B7–B8 cirrhosis, ECOG 0–1, no prior systemic therapy, including HBV/HCV with control. Patients receive the STRIDE regimen: a single priming dose of tremelimumab (CTLA-4 inhibitor) plus durvalumab maintenance (PD-L1 inhibitor) given every 4 weeks until progression or toxicity.

ClinicalTrials.gov ID: NCT06526104

vGRID SBRT: A Phase I Clinical Trial in Unresectable or Metastatic HCC

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

HealthScout AI summary: Adults with unresectable, locally advanced or metastatic HCC (or mixed HCC-CCA), ECOG 0–1 and Child-Pugh A–B7, receive a single-fraction vGRID SBRT dose-escalation (27–47 Gy; de-escalation to 40 Gy in 5 fractions if needed) targeting part of the tumor with high dose while respecting liver/GI constraints. Standard atezolizumab (PD-L1 inhibitor) starts 12–16 days post-SBRT with bevacizumab held for cycle 1 to reduce GI risk.

ClinicalTrials.gov ID: NCT05727787

A Phase II Study of Nivolumab + Ipilimumab in Advanced HCC Patients Who Have Progressed on First Line Atezolizumab + Bevacizumab

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

HealthScout AI summary: Adults with unresectable/advanced or metastatic HCC (BCLC B not amenable to liver-directed therapy or C), Child-Pugh A, ECOG 0–1, who radiographically progressed on first-line atezolizumab plus bevacizumab (excluding rapid progressors) receive nivolumab (PD-1 inhibitor) plus ipilimumab (CTLA-4 inhibitor) induction followed by nivolumab maintenance. Key exclusions include active autoimmune disease requiring systemic therapy, prior severe IO toxicity, uncontrolled HBV/infections, and recent major surgery.

ClinicalTrials.gov ID: NCT05199285

Safety and Immunological Effects of Pembrolizumab Plus Ablative Radiotherapy in Patients With Advanced Adrenocortical Carcinoma

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

HealthScout AI summary: Single-arm study for adolescents and adults with metastatic adrenocortical carcinoma with symptomatic liver metastases and extrahepatic disease, ECOG 0–1, and no prior PD-1/PD-L1/CTLA-4 therapy, evaluating ablative radiotherapy to liver lesions followed by pembrolizumab. Pembrolizumab is an anti–PD-1 monoclonal antibody intended to enhance antitumor T-cell activity, with the RT combination aiming to potentiate systemic immune responses.

ClinicalTrials.gov ID: NCT06066333

A Phase II, Open-Label, Multi-Cohort, Multicenter Study in Patients With Unresectable Hepatocellular Carcinoma and Child-Pugh B7 and B8 Cirrhosis

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

HealthScout AI summary: Adults with unresectable, locally advanced/metastatic HCC and Child-Pugh B7–B8 cirrhosis, ECOG 0–2, and no prior systemic therapy receive either atezolizumab plus bevacizumab (anti–PD-L1 + anti-VEGF) or atezolizumab alone, with emphasis on safety/tolerability in this higher-risk population. Excludes high bleeding risk (e.g., recent/active variceal bleeding), significant autoimmune disease, prior checkpoint inhibitors, and TIPS for the combo cohort.

ClinicalTrials.gov ID: NCT06096779

Regorafenib and Yttrium-90 Radioembolization for Treatment of Unresectable Hepatocellular Carcinoma

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

HealthScout AI summary: Adults with unresectable HCC (Child-Pugh A–B7), no prior systemic therapy, and suitable anatomy for Y-90 TARE receive combined Y-90 radioembolization (TheraSphere) plus regorafenib, an oral multikinase inhibitor of VEGFR1–3, TIE2, KIT, RET, and RAF. Excludes major extrahepatic disease and significant comorbidities; aims to assess disease control and safety.

ClinicalTrials.gov ID: NCT06902246